Type-2 Diabetes Mellitus as a Cardiovascular Disease;La diabetes mellitus tipo 2 como enfermedad cardiovascular

Revista Espanola de Cardiologia Suplementos

Volumn 7, Issue 1, 2007, Pages 9A-22A

  Corbatón Anchuelo, Arturo ^a   Cuervo Pinto, Rafael ^a   Serrano Ríos, Manuel ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Adhesion molecules; Atherogenic dyslipidemia; Nitric oxide synthase; Type 2 diabetes mellitus; Visceral obesity

Indexed keywords

CELL ADHESION MOLECULE;

ARTICLE; ATHEROMATOSIS; CARBOHYDRATE INTOLERANCE; CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE PREDISPOSITION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RISK FACTOR;

EID: 84907914303     PISSN: 11313587     EISSN: 15792250     Source Type: Journal    
DOI: 10.1016/S1131-3587(07)75231-7     Document Type: Article

References (142)

1. King, H., Aubert, R.E., Herman, W.H., Global burden of diabetes, 1999-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998), 1414–1431.
2. Zimmet, P., Alberti, K.G., Shaw, S., Global and societal implications of diabetes epidemic. Nature 414 (2001), 782–787.
3. Laakso, M., Lehto, S., Epidemiology of macrovascular disease in diabetes. Diab Rev 5 (1997), 294–315.
4. Gu, K., Cowie, C.C., Harris, M.I., Diabetes and decline in heart disease mortality in US adults. JAMA 281 (1999), 1291–1297.
5. Huxley, R., Barzi, F., Woodward, M., Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ [accedido 21 Dic], 2006 Disponible en: doi 10.1136/bmj.38678.389583.7C.
6. Amos, A.F., McCarthy, D.J., Zimmet, P., The rising global burden of diabetes and its complications:estimates and projections to the year 2010. Diabet Med 14 (1997), 1–85.
7. Harris, M.I., Epidemiology of Diabetes mellitus among the elderly in the United States. Clin Geriatr Med 6 (1990), 703–719.
8. American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care 21 (1998), 296–309.
9. Lustman, P.J., Clouse, R.E., Identifying novel approaches to diabetes prevention and treatment: the example of depression. Diab Spect 17 (2004), 147–148.
10. Van Hoeven, K.H., Factor, S.M., A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 82 (1990), 848–855.
11. Yarom, R., Zirkin, H., Stammler, G., Rose, A.G., Human coronary microvessels in diabetes and ischaemia. Morphometric study of autopsy material. J Pathol 166 (1992), 265–270.
12. The Diabetes Drafting Group. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centers. The World Health Organisation Multinational Study of Vascular Disease in Diabetics. Diabetologia 28:Suppl (1985), 615–640.
13. Kannel, W.B., Factores de riesgo de coronariopatía: actualización del estudio de Framingham. Hosp Pract 6 (1991), 45–55.
14. UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 13 (1990), 1–11.
15. Haffner, S.M., Lehto, S., Rönnemaa, T., Pÿorala, K., Laakso, M., Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and withour prior miocardial. N Engl J Med 339 (1998), 229–234.
16. Zavaroni, I., Bonora, E., Pagliara, M., Dall'Aglio, E., Luchetti, L., Buonanna, G., et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucosa tolerance. N Eng J Med 320 (1989), 702–706.
17. Zavaroni, I., Dall'Aglio, E., Bonora, E., Alpi, O., Passeri, M., Reaven, G.M., Evidence that multiple risk factors for coronary artery disease exist in persons with abnormal glucose tolerance. Am J Med 83 (1987), 609–612.
18. Liu, Q.Z., Knowler, W.C., Nelson, R.G., Saad, M.F., Charles, M.A., Liebow, I.M., Insulin treatment, endogenous insulin concentration and ECG abnormalities in diabetic Pima Indians: cross sectional and prospective analyses. Diabetes 41 (1992), 1141–1150.
19. Baron, A.D., Cardiovascular Action of Insulin in humans Implications for Insulinsensitivity and Vascular tone. Ferrannini, E., (eds.) Ballieres Clinical Endocrinology and Metabolism. Insulin Resistance and Disease, 1993, Editorial Ballieri Tindall, London, 961–988.
20. Steppan, C.M., Baile, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., et al. The hormone resistin links obesity to diabetes. Nature 409 (2001), 307–312.
21. Baron, A.D., Steiberg, H.O., Vascular actions of insulin in health and disease. Sowers, Jr, (eds.) Endocrinology of the vasculature, 1996, Humana Press, Totowa, 95–108.
22. Jung, F., Haendeler, J., Goebel, C., Zeiher, A.M., Dimmeler, S., Growth factor-induced phosphoinositol 3-OH kinase/Akt phosphorylation in smooth muscle cells: induction of cell proliferation and inhibition of cell death. Cardiovasc Res 48 (2000), 1248–1257.
23. Kooistra, T., Bosma, P.J., Tons, H.A.M., Van den Berg, A., Meyer, R., Princen, C., Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost 91 (1989), 2185–2193.
24. Bergholm, R., Wexterbacka, J., Vehkavaara, S., Seppälä-Lindroos, A., Goto, T., Yki-Järvinen, H., Insulin sensitivity regulates autonomic control of heart rate variation independent of body weight in normal subjects. J Clin Endocrinol Metab 86 (2001), 1403–1409.
25. Berk, B.C., Weintraub, W.S., Alexander, R.W., Elevation of C-reactive protein in «active» coronary artery disease. Am J Cardiol 65 (1990), 168–172.
26. Iluso, G., Biasucci, L.M., Gallimore, J.R., Grillo, R.L., Rebuzzi, A.G., Pepys, M.B., The prognostic value of C-reactive protein and serum amyloid a protein in severe instable angina. N Engl J Med 331 (1994), 417–424.
27. Biasucci, L.M., Iluso, G., Colizzi, C., Rizzello, V., Clinical use of Creactive protein for the prognostic stratification of patients with ischemic heart disease. Ital Heart J 2 (2001), 164–171.
28. Libby, P., Ridker, P.M., Maseri, A., Inflammation and atherosclerosis. Circulation 105 (2002), 1135–1143.
29. Ridker, P.M., Hennekens, C.H., Buring, J.E., Rifai, N., C-reactive protein and other markers of inflammation in the predicction of cardiovascular disease in women. N Engl J Med 342 (2000), 836–843.
30. Ridker, P.M., Rifai, N., Stampfer, M.J., Hennekens, C.H., Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000), 1767–1772.
31. Harris, T.B., Ferucci, L., Tracy, R.P., Corti, M.C., Wacholder, S., Ettinger, W.H. Jr, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106 (1999), 506–512.
32. Ridker, P.M., Rifai, N., Pfeffer, M., Sacks, F., Lepage, S., Elevation of tumor necrosis factor alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 101 (2000), 2149–2153.
33. Hwang, S.J., Ballantyne, C.M., Sharret, A.R., Smith, L.C., Davis, C.E., Gotto, A.M. Jr, et al. Circulating adhesion molecules VCAM-1, ICAM-1 and E-selectin in carotid atherosclerosis and incident coronary Heart disease cases. The Atherosclerosis Risk in Communities (ARIC) study. Circulation 94 (1997), 4219–4225.
34. Ridker, P.M., Buring, J.E., Rifai, N., Soluble P-selectin and the risk of future cardiovascular events. Circulation 103 (2001), 491–495.
35. Koenig, W., Sund, M., Frohlich, M., Fischer, H.G., Löwel, H., Döring, A., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk coronary heart disease in initially healthy middle-aged men: results from the MONICA Ausburg Cohort Study, 1984 to 1992. Circulation 99 (1999), 237–242.
36. Fernandez-Real, J.M., Ricart, W., Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine Rev 24 (2003), 278–301.
37. Siwik, D.A., Chang, D.L.F., Colucci, W.S., Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res, 86, 2000, 1259.
38. Lopes-Virella, M., Virilla, G., Cytokines, modified lipoproteins, and atherosclerosis in diabetes. Diabetes 45:Suppl 3 (1996), 40–44.
39. Barath, P., Fishbein, M.C., Cao, J., Berenson, J., Helfant, R.H., Forrester, J.S., Detection and localization of TNF in human atheroma. Am J Cardiol 21 (1989), 1241–1251.
40. Kaartinen, M., Penttila, A., Kovanen, P., Mast cells in ruptura prone areas of human coronary atheromas produce and store TNF-alpha. Circulation 27 (1996), 87–92.
41. Yudkin, J.S., Kumasi, M., Humphries, S.E., Inflammation, obesity, stress and coronary heart disease:is interleukin-6 the link?. Atherosclerosis 148 (2000), 209–214.
42. Woods, A., Brull, D.J., Humphries, S.E., Genetics of inflammation and risk of coronary heart disease: the central role of interleukin 6. Eur Heart J 21 (2000), 1574–1583.
43. Ridker, P.M., Rifai, N., Stampfer, M.J., Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000), 1767–1772.
44. UKPDS Group. Intensive blood glucose control with sulphonilurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1999), 837–853.
45. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998), 854–865.
46. Ohkubo, Y., Kishikawa, H., Arki, E., Miyata, T., Isami, S., Motoyoshi, S., et al. Intensive insulin therapy prevents the progresión of diabetic microvascular complications in Japanese patients with noninsulin- dependent diabetes mellitus: a randomized prospective 6 year study. Diab Res Clin Prac 28 (1995), 103–119.
47. Suskin, N., McKelvie, R.S., Burns, R.J., Latini, R., Pericak, D., Probstfield, J., Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 21 (2000), 1368–1375.
48. Holzmann, M., Olsson, A., Johansson, J., Jensen-Urstad, M., Left ventricular diastolic function is related to glucose in a middle-aged population. J Intern Med 251 (2002), 415–420.
49. Gaede, P., Vedel, P., Parving, H.H., Pedersen, O., Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 diabetes study. Lancet 353 (1999), 617–622.
50. Malmberg, K., Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 314 (1997), 1512–1515.
51. DeFronzo, R.A., Diabetic nephropathy: etiologic and therapeutic considerations. Diabet Rev 3 (1995), 510–564.
52. Estacio, R.O., Jeffers, B.W., Hiatt, W.R., Biggerstaff, S.L., Gifford, N., Schrier, R.W., The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 338 (1998), 645–652.
53. Deewania, P., Hypertension and Diabetes. Arch Intern Med 160 (2000), 1585–1594.
54. Diabetic Nehropathy. ADA Recommendations. Diabetes Care 23 (2000), S73–S76.
55. DeFronzo, R.A., Diabetic nephropathy: etiologic and therapeutic considerations. Diabetes Rev 3 (1995), 510–564.
56. Ferrannini, E., Buzzyali, G., Bonadonnea, R., Insulin resistance in essential hypertension. N Eng J Med 317 (1987), 350–357.
57. Ferrannini, E., Natali, A., Capaldo, B., Lehtovirta, M., Jacobet, S., Insulin resistance hyperinsulinemia and blood pressure. Role of age and obesity. Hypertension 30 (1997), 1144–1149.
58. Ferrannini, E., Insulin resistance and blood pressure. Reaven, G.M., Laws, A., (eds.) Insulin resistance. The metabolic syndrome X, 1999, Humana Press, Totowa, 281–308.
59. Ferranini, E., Natali, A., Capaldo, B., Lehtovirta, M., Jacob, S., Yki-Jarvinen, H., Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension 30 (1997), 1144–1149.
60. Groop, L.C., Kankuri, M., Shalin-Jantti, C., Ekstrand, A., Nikula-Ijas, P., Widen, E., et al. Association between polymorphism of the glycogen syntase gene and non insulin-dependent diabetes mellitus. N Eng J Med 328 (1993), 10–14.
61. Stenbit, A.E., Tsao, T.S., Li, J., Burcelin, R., Geenen, D.L., Factor, S.M., et al. Glut 4 heterozygous knockout mice develop muscle insulin resistance and diabetes. Nat Med 3 (1997), 1096–1101.
62. Whithers, O.J., Gutiérrez, J.S., Towery, H., Burks, D.J., Ren, J.M., Previs, S., et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391 (1998), 900–904.
63. Barroso, I., Gurnell, M., Crowley, V.E., Agostini, M., Schwabel, J.W., Soos, M.A., et al. Dominant negative mutations in human PPAR? associated with sever insulin resistance, diabetes mellitus and hypertension. Nature 402 (1999), 880–883.
64. Rosengren, A., Welin, L., Tsipogianii, A., Wilhelmesn, L., Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. BMJ 299 (1989), 1127–1131.
65. Kannel, W.B., McGee, L., Diabetes and cardiovascular risk factors: the Framinghan Study. Circulation 59 (1979), 8–13.
66. Mansfield, M.W., Heywood, D., Grant, P.J., Circulating levels of factor VII, fibrinogen and von Willebrand factor and features of insulin resistance in non-insulin dependent diabetes mellitus. Thromb Haemost 75 (1996), 401–406.
67. Steiner, G., Vranic, M., Hyperinsulinemia and hypertrigliceridemia, a vicious cycle with atherogenic potential. Int J Obesity 6:Suppl 1 (1982), 117–124.
68. Grundy, S.M., Bairey Merz, C.N., Brewer, B., Clark, L.T., Hunninghake, D.B., Pasternak, R.C., et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110 (2004), 227–239.
69. Yudkin, J.S., Stehouwer, C.D., Emeis, J.J., C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 19 (1999), 972–978.
70. Recasens, M., Ricart, W., Fernández-Real, J.M., Obesidad e inflamación. Rev Med Univ Navarra 48 (2004), 49–54.
71. Fuller, J.H., Keen, H., Jarrett, R.J., Omer, T., Meade, T.W., Chakrabarti, R., et al. Haemostatic variables associated with diabetes and its complications. BMJ 2 (1979), 964–966.
72. Sartori, M.T., Vettor, R., De Pergola, G., De Mitrio, V., Saggiorato, G., Della Mea, P., et al. Role of the 4G/5G polymorphism of PAI-1 gene promoter on PAI-1 levels in obese patients. Thromb Haemost 86 (2001), 1161–1169.
73. Juhan-Vague, I., Alessi, M.C., Morange, P.E., Hypofibrinolysis and increased PAI-1 are linked to atherosclerosis via insulin resistance and obesity. Ann Med 32 (2000), 78–84.
74. Mavri, A., Alessi, M.C., Juhan-Vague, I., Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases. J Intern Med 255 (2004), 448–456.
75. Falcon, C., Pfliegler, G., Deckmyn, H., Vermylen, J., The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem Biophys Res Com 157 (1988), 1190–1196.
76. Hiramatsu, K., Nozaki, H., Arimori, S., Reduction of platelet agregation induced by euglycaemic insulin clamp. Diabetologia 30 (1987), 310–313.
77. Westerbacka, J., Yki-Järvinen, H., Turpeinen, A., Rissanen, A., Vehkavaara, S., Syrjälä, M., et al. Inhibition of platelet-collagen-gen interaction. An in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol 22 (2002), 167–172.
78. Nakata, M., Yada, T., Soejima, N., Maruyama, I., Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 48 (1999), 426–429.
79. Konstantinides, S., Schäfer, K., Koschnick, S., Losutoff, D.J., Leptindependent platelet aggregation and arterial trombosis suggests a mechanism for atherotrombotic disease in obesity. J Clin Invest 108 (2001), 1533–1540.
80. Conlan, M.g., Folsom, A.R., Finch, A., Davis, C.E., Sorlie, P., Marcucci, G., et al. Associations of factor VIII, and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 70 (1993), 380–385.
81. Juhan-Vague, I., Thompson, S.G., Jespersen, J., Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris. The ECAT angina pectoris group. Arterioscler Thromb 13 (1993), 1865–1873.
82. Meigs, J.B., Mittleman, M.A., Nathan, D.M., Tofler, G.H., Singer, D.E., Murphy-Sheehy, P.M., et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 283 (2000), 221–228.
83. Hayden, M.R., Tyagi, S.C., Is type 2 diabetes mellitus a vascular disease (atheroscleopathy) with hyperglycemia a late manifestation? The role of NOS, NO and redox stress. Cardiovasc Diabetol, 2, 2003, 2.
84. Nash, D.T., Insulin resistance, ADMA levels, and cardiovascular disease. JAMA 287 (2002), 1451–1452.
85. Duplain, H., Burcelin, R., Sartori, C., Cook, S., Egli, M., Lepori, M., et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endotehlial nitric oxide synthase. Circulation 104 (2001), 342–345.
86. Miyamoto, Y., Saito, Y., Kajiyama, N., Yoshimura, M., Shimasaki, Y., Nakayama, M., Endotelial nitric oxide synthase gene is positevely associated with essential hypertension. Hypertension 32 (1998), 3–8.
87. Hingorani, A.D., Liang, C.F., Fatibene, J., Lyon Monteih, A.S., Parsons, A., Haydok, S., et al. A common variant of the endothelial nitric synthase (Glu 298 ? Asp) is a mayor risk factor for coronary artery disease in the UK. Circulation 100 (1999), 1515–1520.
88. Huo, Y., Ley, K., Adhesion molecules and atherogenesis. Acta Physiol Scand 173 (2001), 35–43.
89. Harlan, J.M., Liu, D.Y., Adhesion: it's role in inflammatory disease. 1992, WH Freeman, New York p.18.
90. Johnson-Tidey, R.R., McGregor, J.L., Taylor, P.R., Poston, R.N., Increase in the adhesion molecule P-selectin in endothelium overlying aetherosclerotic plaques:coexpression with intercellular adhesion molecule-1. Am J Pathol 144 (1994), 952–961.
91. Davies, M.J., Gordon, J.L., Gearing, A.J.H., Pigott, R., Woolf, N., Katz, D, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 171 (1993), 223–229.
92. Iiyama, K., Hajra, L., Iiyama, M., Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res 85 (1999), 199–207.
93. Springer, T.A., Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76 (1994), 301–314.
94. Manka, D.R., Wiegman, P., Dinb, S., Sandersb, J.M., Greencet, S.A., Arterial injury increases expression of inflammatory adhesion molecules in the carotid arteries of apolipoprotein E-deficient mice. J Vas Res 36 (1999), 372–378.
95. O'Brien, K.D., McDonald, T.O., Chait, A., Harlan, J.M., Fishbein, D., McCarty, J., et al. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest 92 (1993), 945–951.
96. Brevetti, G., De Caterina, M., Martone, V.D., Ungaro, B., Corrado, F., Silvestro, A., et al. Exercise increases soluble adhesion molecules ICAM-a and VCAM-1 in patients with intermittent claudication. Clin Hemorheol Microcirc 24 (2001), 193–199.
97. Hackman, A., Abe, Y., Insull, W., Pownall, H., Smith, L., Dunn, K., et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 93 (1996), 1334–1338.
98. Belch, J.JF., Shaw, J.W., Kirk, G., McLaren, M., Robb, R., Maple, C., et al. The white blood cell adhesion molecule E-selectin predicts restenosis in patients with intermittent claudication undergoing percutaneous transliminal angioplasty. Circulation 95 (1997), 2027–2031.
99. Mulvihill, N.T., Foley, J.B., Murphy, R.T., Enhanced endothelial activation in diabetic patients with unstable angina and non-Q-wave myocardial infarction. Diabet Med 18 (2001), 979–983.
100. Kannel, W.B., Hjortland, M., Castelli, W.P., Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34 (1974), 29–34.
101. Andersson, B., Waagstein, F., Spectrum and outcome of congestive heart failure in a hospitalised population. Am Heart J 126 (1993), 632–640.
102. Bell, D., Diabetic cardiomiopathy. Diabetes Care 26 (2003), 2949–2951.
103. Devereux, R.B., Roman, M.J., Paranicas, M., O'Grady, M.J., Lee, E.T., Welty, T.K., et al. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation 101 (2000), 2271–2276.
104. Vaur, L., Gueret, P., Lievre, M., Chabard, S., Parre, P., Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria. Diabetes Care 26 (2003), 855–860.
105. Amato, L., Paolisso, G., Cacciatore, F., Ferrara, N., Ferrara, P., Canonico, S., et al. On behalf of the observatorio Geriatrico Regione Campania Group. Congestive Heart Failure predicts the development of non-insulin dependent diabetes mellitus in the elderly. Diabetes Metab 23 (1997), 213–218.
106. Cosme García, J.L., Urrutia, A., González, B., Herreros, J., Altimir, S., Coll, R., et al. Significado pronóstico de la diabetes mellitus en una población con insuficiencia cardiaca: mortalidad e ingreso por insuficiencia cardiaca a 1 año. Med Clin (Barc) 25 (2005), 182–183.
107. De Groote, P., Lamblin, N., Mouquet, F., Plichon, D., McFadden, E., Van Belle, E., et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 25 (2004), 656–662.
108. Dries, D.L., Sweitzer, N.K., Drazner, M.H., Gersch, B.J., Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 38 (2001), 421–428.
109. Domanski, M., Krause-Steinrauf, H., Deedwania, P., Follman, D., Ghali, J.K., Gilbert, E., et al. BEST investigators. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 42 (2003), 914–922.
110. Bauters, C., Lamblin, N., McFadden, E.P., Van Bell, E., Millaire, A., DeGroote, P., Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol 2 (2003), 1–16.
111. Bartnik, M., Malmberg, K., Ryden, L., Managing heart disease. Diabetes and the heart: compromised myocardial function: a common challenge. Eur Heart J Suppl 5:Suppl B (2003), 33–41.
112. Szabo, C., PPAR as a drug target for the therapy of diabetic cardiovascular dysfunction. Drugs News Perspect 15 (2002), 197–205.
113. Hardin, N., The myocardial and vascular pathology of diabetic cardiomyopathy. Coronary Arter Dis 7 (1996), 99–108.
114. Brunetti, P., Perriello, G., Hyperglycemia as cardiovascular risk in type 2 diabetes. Hâncu, N., (eds.) Cardiovascular risk in type 2 diabetes mellitus, 2003, Springer Verlag, Berlin, 22–27.
115. Veresiu, I.A., Assesment of peripheral vascular disease. Hâncu, N., (eds.) Cardiovascular risk in type 2 diabetes mellitus, 2003, Springer Verlag, Berlin, 227–239.
116. Palumbo PJ, Melton LJ. Peripheral vascular disease in diabetes. En: diabetes care in America. 2nd ed. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. NIH Publication. 1995:1468:401-8.
117. Zhou, S., Dickinson, L.C., Yang, Li., Decker, E.A., Identification of hydrazine in commercial preparations of carnosine and its influence on carnosine's antioxidative properties. Analyt Biochem 261 (1998), 79–86.
118. Gribble, F.M., Ashcroft, F.M., Differential sensitivity of beta-cell and extrapancreatic Katp channels to glicacide. Diabetologia 42 (1999), 845–848.
119. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 26 (2003), 977–980.
120. Sarafidis, P., Larasidis, A., Nilsson, P., Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 22 (2004), 1769–1777.
121. González Juanetey, J.R., Grigorian Shamagian, L., Beneficios potenciales de las glitazonas sobre la enfermedad cardiovascular en la diabetes. Situación actual y perspectivas de futuro. Adv Diabetol 21 (2005), 108–117.
122. Choi, D., Kim, S.K., Choi, S.H., Ko, Y.G., Ahn, C.W., Jang, Y., et al. Preventive effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27 (2004), 2654–2660.
123. Dormandy, J.A., Charbonnel, B., Eckland, D.J.A., Massi-Benedetti, M., Moules, I.K., Skene, A.M., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005), 1279–1289.
124. Spanheimer R, Tan M, Yates J, on behalf of the PROactive Investigators. Effects of Long-Term Pioglitazone Therapy on Serum Lipid Profiles in High-Risk Type 2 Diabetes Patients: Result From the PROactive Study. Presentado en el World Congress of Cardiology. Barcelona, España, 2-6 Septiembre, 2006.
125. Heart outcomes prevention evaluation (HOPE) study investigators. Effect of angiotensin converting enzyme inhibitor Ramipril on cardiovascular events in high-risk patients. N Eng J Med 342 (2000), 145–153.
126. Heart outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of Ramipril on cardiovascular and microvascular outcomes in people with Diabetes Mellitus: Results of the HOPE and the MICROHOPE substudy. Lancet 355 (2000), 253–259.
127. Ravid, M., Brosch, D., Levi, Z., Bar-Dayan, Y., Ravid, D., Rachmani, R., Use of enalapril to attenuate decline in renal function in nor-motensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized controlled trial. Ann Intern Med 128 (1998), 982–988.
128. Sano, T., Hotter, N., Kawamura, T., Matsume, H., Chaya, S., Sasaki, H., et al. Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4 year prospective, randomized study. Diabet Med 13 (1996), 120–124.
129. Ahmad, J., Siddiqui, M.A., Ahmad, M., Effective postponement of diabetic nephropaty with enalapril in normotensive type 2 diabetic patients with microalbumniuria. Diabetes Care 20 (1997), 1576–1581.
130. DREAM trial investigators. Effect of Ramipril on the Incidence of Diabetes. N Engl J Med 355 (2006), 1–12.
131. Burnier, M., Brunner, H.R., Angiotensin II receptor antagonists. Lancet 355 (2000), 637–645.
132. Brenner, B.M., Cooper, M.L., Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.H., et al., For the RENAAL Study Investigators: effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes nephropathy. N Engl J Med 342 (2001), 861–869.
133. Pershadsingh, H.A., Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor γ. Int J Biochem Cell Biol 38 (2006), 766–781.
134. Fujimoto, M., Masuzaki, H., Tanaka, T., Yasue, S., Tomita, T., Okazawa, K., et al. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT 4 protein expression in 3T3-L1 adipocitos. FEBS Letters 576 (2004), 492–497.
135. Clemenz, M., Frank, J., Schupp, M., Goebel, M., Unger, T., Kintscher, U., The PPAR-γ activating ARB irbesartan stimulates expression of the insulin-signaling protein CAP and enhances insulin: induced glucose uptake. 2004, American Heart Association Scientific Sessions, New Orleans, Louisiana November 7-10, [Abstract #3850].
136. Vitale, C., Mercuro, G., Castiglioni, C., Cornoldi, A., Tulli, A., Fini, M., et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 4 (2005), 6–8.
137. Derosa, G., Cicero, A.F., Bertone, G., Piccini, M.N., Fogari, E., Ciccarelli, L., et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double blind study. Clin Therap 26 (2004), 1228–1236.
138. Derosa, G., Ragonesi, P.D., Mugellini, A., Ciccarelli, L., Fogari, R., Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism, and the lipid profile in hypertensive, type 2 diabetic patients: A 12-month, randomized, double blind placebo study. Hypertension Res 27 (2004), 264–347.
139. Miura, Y., Yamamoto, N., Tsunekawa, S., Taguchi, S., Eguchi, Y., Ozaki, N., et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 28 (2005), 757–758.
140. Carmena, R., Ascaso, J.F., Dyslipidemia and cardiovascular risk in diabetes. Hâncu, N., (eds.) Cardiovascular risk in type 2 diabetes mellitus, 2003, Springer Verlag, Berlin, 22–27.
141. Laakso, M., Lehto, S., Epidemiology of macrovascular disease in diabetes. Diabetes Rev 5 (1997), 294–315.
142. Pallardo Sánchez, L.F., Herranz de la Morena, L., Prevención de la diabetes mellitus tipo 2 y de sus complicaciones microangiopáticas. Cardiovas Risk Factors 12 (2003), 112–126.